Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group.
about
Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life.Different faces of gastroparesis.Gastrointestinal motility disorders in childrenStomach dysfunction in diabetes mellitus: emerging technology and pharmacologyEffect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trialClinical guideline: management of gastroparesisPharmacotherapy of gastroparesis.Saudi Gastroenterology Association position statement on safety issues associated with the use of domperidoneCardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine.Gastric emptying in diabetes: clinical significance and treatment.Domperidone: review of pharmacology and clinical applications in gastroenterology.Management of diabetic gastroparesis.Diabetic gastropathy and prokinetics.Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting.Determinants of symptom pattern in idiopathic severely delayed gastric emptying: gastric emptying rate or proximal stomach dysfunction?Treatment of gastroparesis: a multidisciplinary clinical review.Gastroparesis: clinical update.Exploratory Study of Tegaserod for Dyspepsia in Women Receiving PPIs for HeartburnPathophysiology and management of gastroparesis.Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting.Review article: the role of gastrointestinal hormones in the treatment of delayed gastric emptying in critically ill patients.Treatment of functional dyspepsia and gastroparesis.Current advances in treatment of gastroparesis.Emerging strategies for the treatment of gastroparesis.Application of SeDeM Expert system in formulation development of effervescent tablets by direct compression.Domperidone is more effective than cisapride in children with diabetic gastroparesis.Long-term cisapride treatment improves diabetic gastroparesis but not glycaemic control.Management of gastroparesis-associated malnutrition.Therapeutic response to domperidone in gastroparesis: A prospective study using the GCSI-daily diary.Benefits of acupuncture for diabetic gastroparesis: a comparative preliminary study.Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index.Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort.Diabetic gastroparesis: current challenges and future prospectsEffectiveness of standard fasting guidelines as assessed by gastric ultrasound examination: A clinical audit
P2860
Q31987954-29D2A7FC-DC69-424E-846A-77872A28F496Q33555343-7E90EC86-D21F-4630-A7FD-F3CEB3411828Q33561975-C6BE298E-4B83-4FF9-A9A7-EF9F624C3059Q33674557-2BEC0ADA-7347-4509-9FF4-78DE5C39041CQ33906991-A2484F63-C768-4534-AB87-772FA6FA67AFQ34034345-8D2BD039-CCC8-4EB7-86FB-82CEA9AEF0A3Q34181990-46A94143-9EC0-4539-B0FB-72171AC9CE25Q34335273-61CB1B1F-6C9F-4AB4-B507-1CF680318CBBQ34379401-409AC97C-ADE2-4E82-B247-E2D925B4D8A6Q34579697-3B21ED09-51DB-47C1-AAC2-A662086D96CCQ34626516-8831AE66-68D3-4A7C-A99F-6210DBD4939DQ34996050-BE5B9395-CB5C-42E0-98E4-0FDD8D27BE7AQ35068007-758AE8C6-72F8-49D3-9419-72996408D2C2Q35566681-67B1EB76-E4E3-41C5-BD91-3F3FFA1E0176Q35761270-16A298B0-7214-4A3D-98D8-560620CCFB49Q36428532-7852F87E-D56F-4FDF-95E1-E14C82F18585Q36476747-722AEF3B-578A-4307-9973-789AF67C05F6Q37262609-0BE02C2D-2279-46A3-967A-564752B1E999Q37436502-F1C19D68-154B-4036-87C1-440D0C2CBA10Q37533007-54B9B8F9-AE55-489C-9F49-B48087CD9D6EQ38123557-EEADCE59-968A-4A94-BC65-649C2F719A5FQ38244400-D13EE5FC-913D-45AA-AB41-17A4B761223CQ38550545-73D2B74E-A5B3-4FCF-8914-E80DDB50385BQ38721476-6419214D-CC63-4BF6-BB85-755B8180839DQ41729240-EF549647-22FB-420A-AE02-445E7768F5D1Q43967110-B5B130B0-FF28-4227-8D1C-C916C1AC6CC4Q44080558-75DE435E-F596-4943-B47D-B705F52750A0Q47766771-EF3E393F-3990-4877-A8FD-7C7B8DDEE97EQ48353515-5FEC565D-846A-4D64-8587-694B7CA5D50FQ51178316-43A94749-596B-43C0-97BA-7C2E2CF58877Q51947880-6EA2B6C6-3F97-46F8-B1F8-0E8F5F0CAB5BQ54199557-1909ADD1-7242-4C41-9C2C-1891E60D2C7BQ57491893-1332D8FE-F3C6-4B90-A0E6-6A7DC879F183Q59137857-97CD8979-91CB-4A1F-A652-3C859D0AD8CD
P2860
Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
name
Domperidone in the management ...... trial. DOM-USA-5 Study Group.
@ast
Domperidone in the management ...... trial. DOM-USA-5 Study Group.
@en
Domperidone in the management ...... trial. DOM-USA-5 Study Group.
@nl
type
label
Domperidone in the management ...... trial. DOM-USA-5 Study Group.
@ast
Domperidone in the management ...... trial. DOM-USA-5 Study Group.
@en
Domperidone in the management ...... trial. DOM-USA-5 Study Group.
@nl
prefLabel
Domperidone in the management ...... trial. DOM-USA-5 Study Group.
@ast
Domperidone in the management ...... trial. DOM-USA-5 Study Group.
@en
Domperidone in the management ...... trial. DOM-USA-5 Study Group.
@nl
P2093
P1476
Domperidone in the management ...... trial. DOM-USA-5 Study Group.
@en
P2093
Broadstone V
McCallum R
Patterson D
Quigley EM
P304
P356
10.1016/S0149-2918(98)80054-4
P577
1998-05-01T00:00:00Z